期刊文献+

持续性非卧床腹膜透析患者微炎症状态影响因素分析及利尿剂对其微炎症状态的影响 被引量:12

下载PDF
导出
摘要 目的探讨持续性非卧床腹膜透析(CAPD)患者微炎症状态的影响因素及利尿剂对CAPD患者微炎症状态的影响。方法检测CAPD患者hs-CRP、IL-6、BNP、PA、UA、TG、CHO、CysC、FPG等指标,作微炎症状态的相关性分析。筛选24例CAPD患者,观察组在控制水盐摄入基础上予以利尿剂(呋塞米)干预,对照组单纯控制水盐摄入处理,收集干预前,干预后第3、6个月时两组患者临床数据。结果影响微炎症水平的因素按程度高低依次为:BNP、CysC、PA,BNP是独立影响因素。观察组经6个月利尿剂干预后各微炎症指标水平较前下降(P<0.05)。观察结束时观察组血压、BNP降低,尿量增加,PA、Hb水平升高,与对照组比较差异均有统计学意义(P<0.05)。治疗前后两组患者TG、CHO、FPG差异无统计学意义,观察组UA水平较干预前下降(P<0.05)。结论容量超负荷、残余肾功能下降、营养不良参与微炎症状态的发生发展,容量超负荷为独立影响因素。利尿剂可通过改善CAPD患者容量负荷进而下调微炎症水平,并随之改善患者的营养不良及贫血状态。
出处 《广东医学》 CAS CSCD 北大核心 2014年第2期226-228,共3页 Guangdong Medical Journal
  • 相关文献

参考文献11

  • 1SCH(O)MING M,EISENHARDT A,RITZ E. The micro-inflammatory state of uremia[J].{H}Blood Purification,2000,(04):327-332.
  • 2CHENG L T. Strong association between volume status and nutritional status in peritoneal dialysis patients[J].{H}American Journal of Kidney Disease,2005,(05):891-902.
  • 3WILCOX C S. New Insights into diuretic use in patients with chronic renal disease[J].Am Soc Nephrol,2002,(03):798-805.
  • 4ARICI M,WALLS J. End-stage renal disease,atherosclerosis,and cardi-ovascularmortality:C-reactive protein the miss link[J].{H}Kidney International,2001,(02):407-414.
  • 5BERGSTROM J,LINDHOLIM B,LACSON E. What are the casue and consequences of the chronic inflammatory stste in chronic dialysis patients[J].{H}Seminars in Dialysis,2000,(03):163-175.
  • 6董捷,王海燕.腹膜透析患者慢性炎症状态与营养不良及心血管病的关系[J].中华肾脏病杂志,2002,18(5):317-321. 被引量:58
  • 7俞雨生,周岩,张炯,陈婷,王生余,王金泉,唐政,黎磊石.胱抑素C测定在腹膜透析患者残余肾功能评价中的应用价值[J].医学研究生学报,2008,21(7):722-726. 被引量:8
  • 8WOODROW G. Extracellular water expansion:part of the malnutrition-inflammation-atherosclerosis syndrome[J].{H}Peritoneal Dialysis International,2006,(05):566-570.
  • 9NEYRA N R,HAKIM R M,SHYR Y. Serum transferrin and serum preal-bumin are early predictors of serum albumin in chronic hemodialysis patients[J].{H}Journal of Renal Nutrition,2000,(04):184-190.
  • 10王昱,鲍晓荣.微炎症在尿酸致早期CKD血管内皮损伤中的作用[J].中国中西医结合肾病杂志,2009,10(11):958-960. 被引量:12

二级参考文献31

  • 1杜国伟,鲍晓荣.早期慢性肾脏疾病患者左室肥厚及其相关因素分析[J].中国临床医学,2005,12(6):1048-1050. 被引量:7
  • 2贾忠辉,谢红浪.糖尿病腹膜透析患者营养不良的预防和治疗[J].医学研究生学报,2006,19(4):377-380. 被引量:9
  • 3覃志成,陈洪宇,王永钧.脂质介导的肾损伤[J].中国中西医结合肾病杂志,2006,7(5):299-301. 被引量:4
  • 4王金泉,刘志红.终末期糖尿病肾病肾替代治疗[J].医学研究生学报,2006,19(7):664-668. 被引量:20
  • 5陈安平,王宗保,易光辉.LOX-1与内皮细胞功能紊乱[J].中国心血管病研究,2007,5(5):375-377. 被引量:2
  • 6Kundhal K, Lok CE. Clinical epidemiology of cardiovascular disease in chronic kidney disease. Nephron, 2005,101 (2) :47 - 52.
  • 7Arici M, Walls J. End - stage renal disease, atherosclerosis, and cardiovascular mortality:is C- reactive protein the missing link? Kidney Int,2001,59(2) :407 - 414.
  • 8Menon V, Greene T. C - reactive protein and albumin as predictors of all - cause and cardiovascular mortality in chronic Kidney disease. Kidney Int,2005,68(2) :766 - 772.
  • 9Pasceri V, Cheng JS, Willerson JT, et al. Modulation of C- reactive protein mediated monocyte chemoattractant protein - 1 induction in human endothelial cells by anti - atherosclerosis drugs. Circulation, 2001,103(21 ) :2531 - 2534.
  • 10Devara JS, Xu DY, Jialai I. C - reactive protein increases plasminogen activator inhibitor- 1 expression and activity in human aortic endothelial cells: implications for the metabolic syndrome and atherothrombosis. Circulation, 2003,107 (3) : 398 - 404.

共引文献75

同被引文献101

  • 1Jacek Rysz,Maciej Banach,Aleksandra Cialkowska-Rysz,Robert Stolarek,Marcin Barylski,Jaroslaw Drozdz,Piotr Okonski.Blood Serum Levels of IL-2, IL-6, IL-8, TNF-α and IL-1β in Patients on Maintenance Hemodialysis[J].Cellular & Molecular Immunology,2006,3(2):151-154. 被引量:14
  • 2Odudu A,Wilke M. Controversies in the management of infective complications of peritoneal dialysis[J2. Nephron Clin Pract, 2011,118(3) :C301-C308.
  • 3Perlstein TS, Weuve J, Pfeffer MA, et al. Red blood cell distribution width and mortality risk in a community- based prospective cohort[J]. Arch Intern Med, 2009,169 (6) :588-594.
  • 4F0rhcz Z,Gombos T,Borgulya G,et al. Red cell distribu- tion width in heart failure: prediction of clinical events and relationship with markers of ineffective erythropoie- sis, inflammation, renal function, and nutritional staterJ]. Am Heart J,2009,158(4) :659-666.
  • 5Pai JK, Pischon T, Ma J, et al. Inflammatory markers and the risk o{ coronary h-cart disease in men and women[J]. N Engt J Med,2004,351(25) :2599-2610.
  • 6Perez Fontan M, Rodriguez-Carmona A, Garcia-Naveiro R,et al. Peritonitis-related mortality in patients undergo- ing chronic peritoneal dialysis[J]. Perit Dial Int, 2005,25 (3) :274-284.
  • 7Nieto-Rios JF, Diaz-Betancur JS, Arbeldez-G6mez M, et al. Peritoneal dialysis-related peritonitis: twentyseven years of experience in a Colombian medical center[J]. Ne- frologia, 2014,34 ( 1 ) : 88-95.
  • 8Felker GM,AIlen LA, Pocock S J, et al. Red cell distribu- tion width as a novel prognostic marker in heart failure: data from the CHARM Program and the Du -ke Databank [J]. J Am Coil Cardiol,2007,50(1) :40-47.
  • 9Oh HJ ,Park JT,Kim JK,et al. Red blood cell distribution width is an indep-endent predictor of mortality in acute kidney injury patients treated with continuous renal re placement therapy[J]. Nephrol Dial Transplant, 2012,27 (2) :589-594.
  • 10Sicaja M,Pehar M,Derek L,et al. Red blood cell distribu- tion width as a progn-ostic marker of mortality in patients on chronic dialysis:a single center,prosp-ective longitudi- nal study[J]. Croat Med J,2013,54(1) :25 -32.

引证文献12

二级引证文献28

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部